BayPine to Acquire CenExel Clinical Research

April 14, 2025

BayPine entered into a definitive agreement to acquire CenExel Clinical Research, a nationwide clinical trial site network focused on complex therapeutic areas. After closing, BayPine will be the majority investor in CenExel alongside Webster Equity Partners, which will retain a minority stake, with management continuing to hold equity.

Buyers
BayPine, Webster Equity Partners
Targets
CenExel Clinical Research, Inc.
Location
United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.